BOSTON SCIENTIFIC CORP (BSX): debt financing — Boston Scientific enters $11B credit facilities; $8B committed for Penumbra acquisition

BOSTON SCIENTIFIC CORP

$3.0B revolving credit agreement matures Feb 2031 with two one-year extension options.
$2.0B 364-day revolving credit agreement tied to Penumbra acquisition; matures 364 days post-close.
$6.0B term loan agreement: $1B Tranche A and $5B Tranche B, both 364-day delayed draw at closing.
Tranche B Loans must be prepaid with net proceeds from equity or debt issuance after closing.
Prior $3.0B 2021 revolving credit agreement terminated upon entry into the new facilities.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

BOSTON SCIENTIFIC CORP incurred revolving credit of $2.000 billion with Wells Fargo Bank, National Association at Term SOFR determined for the interest period plus the applicable margin based on maturing the date that is 364 days from the earlier of (i) the date that any loans under the 364-Day Revolving Credit Agreement are available to be drawn on, or (ii) the.

Instrument: revolving credit
Principal: $2.000 billion
Counterparty: Wells Fargo Bank, National Association
Rate: Term SOFR determined for the interest period plus the applicable margin based on
Maturity: the date that is 364 days from the earlier of (i) the date that any loans under the 364-Day Revolving Credit Agreement are available to be drawn on, or (ii) the
Event: incurrence

Exact text from the filing

On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

BOSTON SCIENTIFIC CORP incurred term loan of up to $1.000 billion with Wells Fargo Bank, National Association maturing 364-day delayed draw.

Instrument: term loan
Principal: up to $1.000 billion
Counterparty: Wells Fargo Bank, National Association
Maturity: 364-day delayed draw
Event: incurrence

Exact text from the filing

by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. Under the Term Loan Credit Agreement, the Company may borrow (i) a 364-day delayed draw term loan in an aggregate principal amount of up to $1.000 billion

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

BOSTON SCIENTIFIC CORP incurred revolving credit of $3.000 billion with Wells Fargo Bank, National Association at Term SOFR determined for the interest period plus the applicable margin based on maturing February 26, 2031.

Instrument: revolving credit
Principal: $3.000 billion
Counterparty: Wells Fargo Bank, National Association
Rate: Term SOFR determined for the interest period plus the applicable margin based on
Maturity: February 26, 2031
Event: incurrence

Exact text from the filing

On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BOSTON SCIENTIFIC CORP entered into 364-Day Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $2.000 billion (effective 2026-02-26).

Action: entry
Agreement: credit facility
Counterparty: Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto
Value: $2.000 billion
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BOSTON SCIENTIFIC CORP entered into 2026 Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $3.000 billion (effective 2026-02-26).

Action: entry
Agreement: credit facility
Counterparty: Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto
Value: $3.000 billion
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BOSTON SCIENTIFIC CORP entered into Term Loan Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $6.000 billion (effective 2026-02-26).

Action: entry
Agreement: credit facility
Counterparty: Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto
Value: $6.000 billion
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026, the Company entered into a $6.000 billion term loan credit agreement (the “ Term Loan Credit Agreement ” and together with the 2026 Revolving Credit Agreement and the 364-Day Revolving Credit Agreement, the “ 2026 Credit Agreements ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent.

View on SEC.gov

7 debt financings filed in the last 30 days. Browse all debt financings →

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-26-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.